Sunday, December 22, 2024

Healthcare

OSTX’s OST-HER2: A Potential Game-Changer for Osteosarcoma (NYSE-A: OSTX)

ROCKVILLE, Md. & NEW YORK, August 02, 2024--(BUSINESS WIRE)--OS Therapies Incorporated ("OS Therapies" or the "Company") (NYSE-A: OSTX), a Cancer Immunotherapy and Antibody Drug Conjugate...

OS Therapies Leading the Way to Breakthroughs in Cancer Treatment

OS Therapies focuses on developing advanced treatments for osteosarcoma, addressing a significant unmet medical need. With an estimated $1.72 billion market for osteosarcoma and a...

NurExone Biologics: Promising Future in Regenerative Medicine

NurExone Biologics is developing exosome-based therapies for non-invasive treatment of central nervous system injuries, with their lead product, ExoPTEN, showing significant promise in preclinical...

RenovoRx’s Breakthroughs in Targeted Cancer Treatments

RenovoTAMP™ Technology: Innovative targeted chemotherapy delivery system. Clinical Validation: Supported by recent publications and new studies. Market Potential: Positioned within a projected $220.5 billion cancer therapy...

NurExone Biologic Advances Glaucoma Research with Cutting-Edge Exosome-Based Therapies (TSXV: NRX, OTCQB: NRXBF)

TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a...

Popular

Subscribe